Table 4.
Model Performance in Predicting Aminoglycoside-induced Hearing Loss
| Audiometric HL in Development Cohort (250–8000 Hz) | Audiometric HL in Validation Cohort (250–8000 Hz) | High-frequency HL in Validation Cohort (9000 Hz–16 000 Hz) | Clinically Determined HL Validation Cohort | |
|---|---|---|---|---|
| AUC (95% CI) | 0.71 (0.64–0.79) | 0.69 (0.56–0.81) | 0.81 (0.69–0.92) | 0.60 (0.54–0.66) |
| Hosmer-Lemeshow Goodness-of-fit | χ 2[8] = 6.10 (P = .636) | χ 2[8] = 8.03 (P = .431) | χ 2[8] = 6.48 (P = .593) | χ 2[8] = 4.34 (P = .825) |
| Cutoff of 80% predicted probability, % | ||||
| Sensitivity | 22.77 | 31.15 | 84.42 | 0.00 |
| Specificity | 93.65 | 87.50 | 56.25 | 100.00 |
| PPV | 85.19 | 82.61 | 90.28 | . |
| NPV | 43.07 | 40.00 | 42.86 | 60.10 |
| Cutoff of 40% predicted probability, % | ||||
| Sensitivity | 90.10 | 100.00 | 97.40 | 52.44 |
| Specificity | 23.81 | 12.50 | 0.00 | 58.30 |
| PPV | 65.47 | 68.54 | 82.42 | 45.50 |
| NPV | 60.00 | 100.00 | 0.00 | 64.86 |
Abbreviations: AUC, area under receiver operating characteristic curve; CI, confidence interval; HL, hearing loss; NPV, negative predictive value; PPV, positive predictive value.